硼替佐米治疗淋巴瘤的临床研究进展

Progress of clinical studies of bortezomib in the treatment of lymphoma

硼替佐米是一种26S蛋白酶体的可逆性抑制剂,通过抑制肿瘤细胞NF-κB通路等机制产生杀肿瘤作用,于2003年在美国上市,并于2006年被美国食品药品监督管理局批准用于套细胞淋巴瘤的治疗。除了针对套细胞淋巴瘤,亦有研究报道硼替佐米单药或联合其他药物可治疗多种生发中心和非生发中心来源的B细胞淋巴瘤、T细胞淋巴瘤和霍奇金淋巴瘤的有效性和安全性。根据化疗方案的不同,硼替佐米的给药频次为1周1次或1周2次。本文综述了硼替佐米治疗各类淋巴瘤的有效性及安全性,对两种给药方案进行汇总比较,为临床使用硼替佐米治疗淋巴瘤提供依据。

As a reversible inhibitor of 26S proteasome,bortezomib suppresses the activation of NF-κB pathway in tumor cells,thus exerts its anti-cancer activity.It was first put into market in 2003,and subsequently,approved by the USA Food and Drug Administration for treating mantle cell lymphoma in 2006.In addition tomantle cell lymphoma,extensive research and clinical trials have carefully examined to ensure the efficacy and safety of bortezomib monotherapyor combined with other drugs in the treatment of B-cell lymphoma,T-cell lymphoma,and Hodgkin′s. The frequency of the administration of bortezomib can be once or twice a week,based on different chemotherapy regimens.Here,we review the efficacy and safety profiles of bortezomib,compare the two different regimens of bortezomib administration,and provide evidence support for the clinical application of bortezomib.